2900016B01Rik Inhibitors
Kbtbd11 inhibitors include a spectrum of chemicals that act on proteasome activity, ubiquitination pathways, and various cellular signaling cascades. These compounds do not inhibit Kbtbd11 directly but can interfere with the cellular milieu and processes that are central to the protein's function. For instance, proteasome inhibitors like MG-132, Bortezomib, Lactacystin, and Epoxomicin can lead to the accumulation of ubiquitinated proteins, which may impact the function of proteins such as Kbtbd11 that are involved in the ubiquitination process. By preventing the degradation of these proteins, there is a possibility that Kbtbd11's interactions with its substrates or its role in ubiquitin-mediated signaling could be altered.
Furthermore, chemicals like MLN4924 disrupt the NEDD8 pathway, which is crucial for the activity of E3 ubiquitin ligases, a category of enzymes Kbtbd11 might be associated with. This can lead to widespread effects on protein ubiquitination and stability, affecting Kbtbd11's potential role in these processes. Compounds that modulate signaling pathways, such as Curcumin, Resveratrol, Wogonin, SB-216763, PD98059, LY294002, and Rapamycin, act on diverse aspects of cellular function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that can prevent the degradation of ubiquitinated proteins, possibly increasing competition for Kbtbd11's BTB domain. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Another proteasome inhibitor that can lead to the accumulation of proteins that might outcompete Kbtbd11 for substrate binding. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Specific proteasome inhibitor that can alter the protein turnover, potentially affecting Kbtbd11-mediated ubiquitination processes. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Selectively inhibits the chymotrypsin-like activity of the proteasome, which might perturb the degradation pathway of proteins related to Kbtbd11. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
Inhibits the NEDD8-activating enzyme, which can indirectly affect the ubiquitination process where Kbtbd11 might be implicated. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
A compound that can modulate various signaling pathways, potentially altering the cellular context in which Kbtbd11 operates. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Influences multiple signaling pathways and could modify the cellular environment of Kbtbd11's activity. | ||||||
Wogonin, S. baicalensis | 632-85-9 | sc-203313 | 10 mg | $200.00 | 8 | |
A flavonoid that can interfere with various signaling cascades, possibly affecting Kbtbd11 indirectly through these pathways. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
A GSK-3 inhibitor that can alter Wnt signaling, potentially impacting pathways where Kbtbd11 is involved. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An MEK inhibitor which can alter MAPK signaling, potentially impacting Kbtbd11's function. | ||||||